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Abstract
The possibility of decreased prostacyclin (PGI2) in
preeclampsia-eclampsia is currently being studied by sev
eral laboritories. Because of prostacyclin's various
actions (platelet aggregation inhibition, vasodilation, stim
ulation of renin release, and possible inhibition of the hy
pertensive effects of angiotensin II), an increase in the
peripheral activity of this chemical could explain much of
the altered physiology of normal pregnancy. A relative de
crease in peripheral activity could tie together the various
pathophysiological findings of preeclampsia-eclampsia.
Therefore, plasma 6-keto PGFxa, the stable nonenzymatic
metabolite of prostacyclin, was measured in women with pre
eclampsia, and in those women of various gestational ages
having a normal pregnancy. The detection method, radioimmuno
assay, could not be internally validated. It appears that
the major problem with the assay was in sample preparation.
Plasma 6-keto PGFxa may be elevated in normal pregnancy.
A decrease in plasma values was seen in those with preeclamp
sia as compared to normals of the same gestational age. In
addition, plasma 6-keto PGFjCX was found to correlate with
platelet count in the preeclamptic women.
The results of this study cannot be accepted as reliable,
but instead should be accepted as impetus for further study.
Gas- Chromatography-Mass Spectrometry (GC-MS) of some of the
samples could be used for verification of this work. Platelet
aggregation inhibition bioassay, along with confirmation by
GC-MS, would be the best method for future study.
If PGI2 activity and concentrations are found to truly
be decreased, not only would the mechansim of preeclampsia-
eclampsia become more clear, but a more acceptable treatment
for the disease would be suggested.
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1I. Preeclampsia-eclampsia
A. Clinical Definitions
Preeclampsia-eclampsia is a common disease of preg
nancy, with an incidence of about 3$ of all pregnancies.
The etiology is unknown, despite decades of intensive
research.
The change in definitions and classifications of hy
pertensive diseases of pregnancy reflects the realization
that several disease processes with several etiologies are
involved. The old term "toxemia of pregnancy" was former
ly applied to any disorder involving hypertension, protein
uria, or edema in pregnancy or the puerperium. In 1972 the
Committee on Terminology of the American College of Obstet
ricians and Gynecologists (1) devised the following classi
fication:
preeclampsia Hypertension with proteinuria, edema, or both
induced by pregnancy in the twentieth week of gestation or
later, or before the twentieth week if there is hydatidiforra
change.
eclampsia Convulsion not caused by neurological disease
in a woman who fulfills the criteria for preeclampsia.
superimposed preeclampsia-eclampsia Either disorder in a
woman with chronic hypertensive vascular disease or kidney
2disease. (Blood pressure must rise 30 mm Hg systolic or 15
mm Hg diastolic. )
chronic hypertensive disease Persistent elevation of
blood pressure before the twentieth week or beyond six weeks
postpartum.
gestational hypertension Hypertension developing in the last
half of pregnancy or the first 24 hours postpartum, without
proteinuria or edema.
gestational edema Generalized edema that persists after
twelve hours of bedrest, or five or more pounds of weight
gain in one week.
gestational proteinuria in pregnancy not induced by hyper
tension, infection, edema, or known vascular or renal dis
ease.
hypertension Diastolic pressure of 90 mm Hg or more; or
systolic pressure of 140 mm Hg or more ; or a rise of diast
olic pressure of 15 mmHg or more; or a rise of 30 mm Hg
systolic or more which occurs on two separate occasions at
least six hours apart.
proteinuria 0.3 g/l of protein in urine collected over a
twenty four hour period.
edema weight gain of at least 1 kilogram in one week when
accompanied by generalized edema.
Preeclampsia is defined as either mild or severe. It is
severe if any of the following occur:
31) blood pressure greater than 160 systolic or 110
diastolic that does not decrease with hospital
ization and bedrest.
2) at least 5 grams proteinuria in twenty-four hours,
or 3 - 4 quantitative.
3) oliguria (less than 400 cc of urine per day)
4) cerebral or visual symptoms
5) epigastric or right upper quadrant pain.
6) pulmonary edema or cyanosis.
7) thrombocyxopenia
8) hepatocellular damage.
9) fetal growth retardation.
Seven to ten percent of all pregnancies are complicated
by hypertension. About half of these are due to chronic
hypertension and half due to preeclampsia. (2) Despite its
high incidence, studies of the disease in the past have been
hampered by the lack of precise diagnoses and definitions.
For example, when proteinuria and hypertension have been
present before conception, they can often disappear
during the third trimester, only to reappear in the third
and continue their presence after delivery. (3) Thus dif
ferentiating between preeclampsia, chronic hypertensive
disease, and superimposed preeclampsia can often be done
only retrospectively.
B. Pathophysiology
1. Vascular Changes
Vasospasm is a basic component of preeclampsia. The
hypertension of preeclampsia-eclampsia is due to wide
spread systemic arteriolar vasospasm ( 3.4,5) t which causes
increased peripheral resistance. Although evident through-
4out the body, it is thought to be most significant in the
kidneys and uterus. (6) The spasm is segmental, leading to
areas of alternating dilation and contraction and inter
mittent interruption of capillary circulation.
The plasma volume in normal pregnancy is increased
forty to fifty percent over normal nonpregnant levels. (7)
This is only partially explained by the physiologic increase
in aldosterone. In preeclampsia, the increase in plasma
volume is less or not evident. In severe disease, the plasma
volume may decrease as much as thirty to forty percent (8)
despite an increase in total body water and in sodium reten
tion. The smaller intravascular volume and space makes pre
eclamptic women much less tolerant to fluid overload or blood
loss. (9)
Vascular sensitivity is increased in women who devel
op preeclampsia. In normal pregnancy, there is a two-fold
increase in renin, RPA, angiotensin, and aldosterone (6,10,22,
11) and a fifty percent increase in cardiac output (12),
but blood pressure is decreased. This occurs because a re
fractoriness to angiotensin II 's hypertensive effects devel
ops. This refractoriness is not related to blood volume or
angiotensin II levels. (13) The increases in the renin-
angiotensin-aldosterone system contribute to the physiologic
hypervolemia while blood pressure remains low due to vascu
lar insensitivity. Gant (14) showed that an increase in
sensitivity to the hypertensive effect of angiotensin II
5occurs in preeclampsia, and that this change antedates the
onset of hypertension.
An increase in vascular sensitivity to other pressor
hormones such as norepinephrine and vasopressin has been
shown in preeclamptics. (15) In fact, a pressor response
to lying supine after lying in the left lateral recumbent
position has been shown in women who are destined to become
hypertensive. (11) Thus it appears that there is a definite
vascular hypersensitivity in women who will develop preeclam
psia.
2. Endocrinological Changes
The increase in plasma renin, angiotensin II, and aldos
terone that occurs normally in pregnancy is significantly
blunted in preeclampsia. (6,10,11,16) Vasopressin (17),
deoxycorticosterone (15) » and progesterone (18) levels
are not different from levels seen in normal pregnancy.
Renin is produced in both the uterus and the juxta
glomerular apparatus of the kidney. Part of the decrease
in renin release may be due to the inhibitory effects of
sodium retension and hypertension on the JGA.
Prostaglandins are known to help regulate the release
of renin, at least in the kidney. Recent evidence (19,20)
that one of the prostaglandins may be the final common path
way for the different signals (sodium depletion, hypoten
sion, hemorrhage, dehydration, constriction of the renal
artery or aorta) that increase renin output. (21) The most
likely prostaglandin is prostacyclin. It is the major
6product of arachidonic acid metabolism in the renal arterial
tree, and prostacyclin is known to cause renal renin release
in vitro. (12,19,3)
3) Uteroplacental Changes
It is commonly thought that placental perfusion is
decreased in women with preeclampsia (15) although precise
blood flow measurment techniques are not yet available for
use in pregnant women. The rate of dehydroisoandrosterone
sulfate (DS) being converted into estradiol 173 by the
placenta has been shown to reflect placental blood flow.
(23.24) Normally, this conversion increases steadily
throughout pregnancy. In women who later develop hyperten
sion, the conversion at first is greater than in normals,
and then drops as hypertension develops. The excessive
clearance levels antedating preeclampsia may correlate not
with increased placental blood flow, but with "hyperplacen-
tosis," an excess of functioning placenta. Preeclampsia
occurs with higher frequency in those with hydatidiform
mole, or in maternal diabetes, erythroblastosis fetalis,
and multiple gestation, all conditions in which there are
large placentas. (15)
A definite morphological difference can be seen in the
placental bed of women with preeclampsia. A lack of
"physiological changes" in the uterine spiral arteries of
preeclamptics has been shown by several investigators. (25,
726,27) In normal preganacy, the spiral arteries dilate
from the distal end proximally into the myometrial segments
figure 1).(27)
PRE-ECLAMPSIA
fig. 1. Spiral arteries in normal and preeclamptic
pregnancies. From (27)
This is caused by migrating endovascular trophoblast cells
replacing the reactive musculoelastic tissue that lines the
arteries. Such tissue infiltrates in two waves; one into
the decidua, then after a four to six week time lag, into
the myometrail spiral arteries. In preeclamptics, the chang
es are restricted to the decidual segments. Some phenomenon
appears to inhibit the second wave on endovascular tropho
blastic infiltration, resulting in a relatively narrowed
deciduomyometrial junction and the continued presence of
reactive musculoelastic cells surrounding the arteries.
With the onset of clinical preeclampsia, another placen
tal vascular lesion occurs. Focal areas of necrosis through
the vascular walls develops. This "acute atherosis" (25i
26) is seen only in the small uterine vessels. Elecronmicro-
scopic evidence shows early accumulation of lipid in the myo-
iritimal cells, and necrosis of medial smooth muscle. This
8later advances to lesions with numerous macrophages present
and with fibrin deposition. (27)
4) Disseminated Intravascular Coagulation
During uncomplicated pregnancy, there is an increase
in many of the factors of coagulation, such as fibrinogen,
prothrombin, factors VIII, VII, IX, and X, soluble fibrin,
and fibrin degradation products. (12,28,29,30) Fibrinolysin
is slightly decreased, as is the platelet count.
With preeclampsia, there is greater coaguability and
a decrease in blood volume. (28) In the hypercoaguability
of preeclampsia, changes are in the same direction as in
normal pregnancy, but of a greater degree. This degree
reaches the level of manifest overcompensated disseminated
intravascular coagulation (DIC), with severe thrombocyto
penia, high fibrinogen, and disseminated intravascular ob
structions, in about 3^ of preeclamptics and 9% of eclamptics.
(28) About 15/o of all preeclamptics develop some degree of
thrombocytopenia.
Coagulation parameters can be used to monitor the sever
ity of the disease. Platelet count is lower and platelet
lifespan is shorter in preeclamptics (5»1 days) as compared
to normals (8.9 days) and nonpregnants (9^1 days). (31)
This is due to increased platelet consumption and micro-
thrombi formation, which may be responsible for peripheral
organ damage. Platelet count, platelet serotonin levels,
9fibrin degradation products, and Factor VIII concentrations
have been shown to parallel the severity of preeclampsia.
(30,32) Thus the hypercoagulability of preeclampsia appears
to be part of a continuum between the lov/ level chronic intra
vascular coagulation of normal pregnancy, and DIC seen in
a subgroup of preeclamptics and eclamptics. This concept
agrees with the commonly held idea that coagulation changes
in preeclampsia are probably secondary to a more basic pro
cess.
5. Renal Changes
In normal pregnancy, glomerular filtration rate (GFR)
and renal blood flow (RBF) are increased over nonpregnant
values. This situation is reversed in preeclampsia. As
the disease becomes more severe, there is a progressive
decrease in renal function ( lowered GFR and lower clear
ances of inulin.uric acid, creatinine) along with decreased
renal perfusion. (4,15,33) The proteinuria seen in the
disease is a nonselective middle molecular weight proteinur
ia consistent with functional glomerular lesions. (33.34)
One study suggested that there might be two forms of protein
uria; one due to the vasoconstrictor effect of hypertension
(with relatively good fetal prognosis) and one due to mem
braneous changes (with poorer fetal prognosis). (35)
Histologic changes found in kidney biopsies and at
autopsies are common. At the present time, there is de-
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bate over the existence of a pathognomonic kidney lesion.
Glomeruli are usually enlarged with dilated capillary loops,
foamy swelling of the endothelial cells, and subendothelial
deposits of protein, together called glomerular capillary
endotheliosis. (15,36) The lesion has never been found in
nonpregnant women or in men. Fibrin/fibrinogen, immunoglob
ulins (IgG and IgM) and complement deposition are less con
stant features. On rare occasions, renal cortical necrosis
occurs secondary to spasm of the renal arteries. No mor
phologic changes in the renal arterioles have been shown.
The presence and duration of proteinuria corresponds to
the occurance and severity of renal lesions. (37)
6. Hepatic Changes
Periportal hemorrhagic necrosis was considered former
ly to be a characteristic of eclampsia. This lesion was usu
ally found in fatal cases that went to autopsy. In liver
biopsies done on six preeclamptics and twelve eclamptics, the
liver biopsies appeared normal. (15) Liver function tests
are rarely abnormal in the disease ; SGOT and SGPT are occa
sionally raised, and bilrubin is rarely elevated, although
one r sport noted SGOT and SGPT elevations in eclamptics but not
preeclamptics. (38) Most investigators now consider the
pathological changes in the liver to be variable, and most
likely to be secondary to the more basic vascular/coagula
tion abnormalities seen in the disease.
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7- Cardiopulmonary Changes
The heart is subjected to the hemodynamic stresses
of decreased intravascular volume and increased peripheral
resistance. in preeclampsia. Heart failure from circulatory
overload (due to overly vigorous intravenous fluid administra
tion without correction of vasospasm) has occured in some
cases. (15.39) Pulmonary edema is often found at autopsy.
Cardiorespiratory failure, along with cerebral hemorrhage,
account for most of the maternal deaths occurring in pre
eclampsia-eclampsia. It appears that these events are not
part of the primary disease process, but occur from overtax
ing the cardiovascular system with severe hemodynamic stres
ses.
Pulmonary arteriolar resistance has been measured by
Swan-Ganz catheter in three severe preeclamptics, and was
shown to be at or below nonpregnant levels. ( 5 ) Although
no data is available for arteriolar resistance in normal
pregnant women, this finding indicates that the pulmonary
vasculature is not involved in the vasospasm seen throughout
the systemic circulation.
8. Cerebral Changes
The major brain lesions found at autopsy in women who
died from eclampsia are edema, hyperemia, thrombosis , and hem
orrhage, which varies from petichiae to gross hemorrhage.
Cerebral bleeding is one of the major causes of death. Hem-
12
orrhagic lesions are often found in the brains of women
who died of other causes. (15)
Nonspecific electroencephalographic changes usually
exist for some time after the eclamptic seizures. Coma for
up to 3 days was reported in six of a series of fifty-two
preeclamptics. (39) The cause of eclamptic seizures and
their link to the pathological changes in preeclampsia
are still unknown. Some young women may have seizures with
a blood pressure of only 145/85, while others can v/ithstand
pressures of 180/120 without convulsions.
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II. Prostaglandins and Preeclampsia-eclampsia
A. Metabolites and Actions
The metabolites of arachidonic acid form a group of
very potent compounds with a variety of vasoactive and other
effects. They are present in nearly every tissue studied to
date.
Precursors are stored as C20 ^ fatty acid esters with
in cell membranes. (42) Stimuli such as hormones, antigen
challenge, collagen, and thrombin stimulate the release of
fatty acids (mostly archidonic acid) by a number of acyl-
hydrolases such as phospholipase A2 and triglyceride lipase.
Platelet release of arachidonic acid may involve several
enzymes such as phospholipase C and diglyceride lipase. (43)
Once arachidonic acid is released, it is quickly met
abolized by one of two different pathways. It can be con
verted by by fatty acid lipoxygenase into the hydroxyacids
HPETE (15-hydroxy-5.8,ll,13-eicosatetraenoic acid) and
HETE (hydroxyeicosatetraenoic acid), and to the leukotrienes.
The required enzyme for this pathway has so far only been
found in platelets, white cells, and lung tissue. The more
common pathway involves conversion by fatty acid cyclooxygen-
ase ( also called prostaglandin endoperoxide synthetase) into
14
the 15-hydroxy prostaglandin endoperoxides PGG2 and PGH2.
(43,44,45) PGG2 and PGH2, with half lives of about five min
utes at 37 C, are the intermediates in the synthesis of
prostaglandins, thromboxanes, and prostacyclin, (fig. 2)
Agents that are known to inhibit the various steps of
arachidonic acid metabolism are shown below. (44,46)
glucocorticoids
phospholipids
phospolipase A2 , etc.
arachidonic acid
non-steroidal
antiinflam-
mitory agents
(Indomethacin,
ASA)
.==>
fatty acid cyclooxygenase
Imidazole
dipyridamol
cAMP -
dibutyryl cAMP
Zn
Cd
Burimamaide
PGG
-PGH
T~l
HTT PGEa FGD~ PGF~a
thromboxane
synthetase
Nicotine
Hydroxy-
arachidonic
acid
HETE
Prostacyclin
Synthetase
*
thromboxane A2
(TXA2)
thromboxane B2
(TXB2)
Prostacyclin
(PGI2)
6-keto PGFxa
Fig. 2. Arachidonic Acid Metabolism.
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Two of the most studied products are the vasoactive chem
icals thromboxane A2 (TXA2) and prostacyclin (PGI2), which
act as natural antagonists. TXA2 is made chiefly by the
platelets, and is a potent vasoconstrictor and stimulator
of platelet aggregation. Prostacyclin, made by the vascular
endothelium and other tissues, is a potent vasodilator and
platelet aggregation inhibitor. An extensive research ef
fort surrounding these two products is being conducted be
cause it is thought that an inbalance between these two could
be a final common pathway in the development of essential
hypertension and cardiovascular degeneration.
1) Thromboxane A2
The chemical structure of TXA2 was first described in
1975* (47) TXA2 causes irreversible platelet aggregation
and platelet release of ADP, serotonin, platelet factor IV,
calcium, lysosomal enzymes, HETE (an inhibitor of prostacy
clin synthetase), a smooth muscle growth stimulating sub
stance, and more TXA2. (45) TXA2 also causes vascular
smooth muscle contraction.
PGH s is converted to TXA2 by thromboxane synthetase, an
enxyme found in platelets and the microsomal fraction of
tissue homogenates. (44) Originally called Rat Aorta Con
tracting Substance, TXA2 has a half life of 32 minutes at
37 C and pH 7.4. It breaks down spontaneously into throm
boxane B2 (TXB2), which is a stable, inactive metabolite.
16
(48) No other metabolites have been reported.
Selective inhibition of TXA2 synthesis would theor
etically be important for the prevention of cardiovascular
disease. Aspirin was initially thought to selectively
block platelet cyclooxygenase as compared to vessel wall
cyclooxygenase. (49) It is now apparent that aspirin
binds irreversibly to cyclooxygenase in both tissue?- . How
ever, circulating platelets lack the ability to synthesize
new enzyme during its nine day life in the bloodstream.
Endothelium is able to make new cyclooxygenase. (45) Thus
a low dose ASA could be useful in increasing the ratio of
prostacyclin/thromboxane. Clinical studies on aspirin's
effectiveness are not complete.
A more direct approach would be to specifically block
thromboxane synthetase. Several specific compounds, such
as imidazole, dipyridamol, cAMP, dibutyryl cAMP, and bur-
imamide have been found to be inhibitory. (44,46)
2) Prostacyclin
Prostacyclin, or 9-deoxy-6,9-epoxy-5-PGFxa, was first
discovered in 1976. Its platelet aggregation inhibiting
action was the basis for its bioassay even before the chem
ical structure was elucidated. (50.51) Production of PGI2
was shown to be highest in endothelial cells, (52,53) and
it is the major product of arachidonic acid metabolism in
the corpus luteum, human follicular tissues, uterus, kid-
17
neys, and bovine seminal vescicles.
Prostacyclin has a half life of two to three minutes
at 37 C and pH 7.5. It is known to break down nonenzymaticly
into its inactive metabolite 6-keto PGFjOt. (45,51) One group
(43,54) suggested that not only does FGI2 break down into
several metabolites besides 6-keto PGFjd, but that one of
its metabolites, PGElt may be the true vasodiating and plate
let aggregation inhibiting substance (fig. 3* ) This is
currently a controversial area, and supporting data for this
opinion has not been repeated by other labs.
PGI,
in lungs/ m
blood
vessels'
9-hydroxy-
prostagland
dehydroge
6-keto PGFxa
( inactive)
6,15 diketo 6,15 diketo PGFxa
13,14 dihy- (inactive)
dro PGFjd
( inactive )
6-keto PGSj
(active)
fig. 3. Proposed PGI2 Metabolism (43)
Although most of the prostaglandins are thought to
act as autocoids (locally acting hormones), it is pos
sible that PGI2 acts as a circulating hormone. The "pri
mary" prostaglandins, such as PGE2, PGF2 , and PGA, are
rapidly converted in the lungs by 15-hydroxyprostaglandin
18
dehydrogenase. However, PG[2 has been shown to pass
through the lungs without breakdown. Venous PGIa infusion,
but not PGE2 infusion, causes systemic hypotension in dogs,
indicating recirculation. (20) Prostacyclin may even be
released from the lung endothelium. (44)
Besides platelet aggregation inhibition and vasodila
tion, PGI2 has been shown to be involved in at least two
regulatory mechanisms. The kallikrein-bradykinin system
and the renin-aldosterone angiotensin system both have some
apparent regulation by prostaglandins, most probably prost
acyclin. The kallikrein-bradykinin system's involvement with
prostaglandins has not been completely elucidated.
Prostacyclin or prostacyclin-like compounds are known
to influence the renin-angiotensin-aldosterone system in at
least three ways: 1) Prostacyclin causes release of renin
secretion from the kidney and possibly the gravid uterus (43,
56); 2) prostaglandins are released from the kidney by angio
tensin II; and 3) Prostaglandins have been implicated in
regulating vascular sensitivity to the hypertensive effect
of angiotensin II (fig. 4) (43,56,57,58)
& . angiotensinogen
—*• renin ^"»|
angiotensin I
PG<° angiotensin II ^PG
aldosterone hypertension
fig. 4. Effects of Prostaglandins on the renin-
aldosterone - angiotensin system.
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Secretion of renin from the renal cortex has been shown
to be stimulated by the direct action of PGI2. (59) Intra-
— ft
renal infusion of PGI2 at 10" g/kg/ml leads to l80fo increase
in renin secretion and a 35$ increase in renal blood flow.
PGE2 and PGD2 had lesser pressor effects. (20 ) Prostacyclin
infusion has been shown to increase renin activity in nor
mal men. (56)
Prostacyclin and /or prostacyclin-like substances are
thought to regulate angiotensin II output and its hyperten
sive effects, and so help maintain renal blood flow during
variations in blood pressure and total blood volume. PGE
and PGI2 output from the renal medulla increase with infusion
of angiotensin II. (19) Prostacyclin-like material has been
shown to be released from the kidney with infusion of angio
tensin II, leading to blunted vasoconstrictor and antidiur
etic effects. When indomethacin is given to block prost
aglandin synthesis, the vasoconstrictor and antidiuretic
actions are no longer blunted. (6 ,62)
Prostacyclin (and/or another prostaglandin) could then
regulate the system as follows: Hypotension and/ or hypo
volemia signal renin release from the kidney (via prosta
cyclin. ) This leads to increased angiotensin II and aldost
erone levels, with resultant increased water and salt reten-
sion, and vasoconstriction. In the kidney, angiotensin II
triggers prostaglandin release (mostly PGE and PGI2), which
acts locally as a vasodilator and as stimulus for further
renin release, with perhaps slight systemic action. The
20
systemic vasoconstriction and renal vasodilation would pro
tect the renal blood supply during periods of hemodynamic
stress. Differential output of prostaglandins may also
effect zonal distribution of renal blood flow, (43)
B. Prostaglandins in Pregnancy and in Preeclampsia
1) Prostaglandin E
Prostaglandins have been proposed as the regulators of
uterine blood flow for many years. (63,59,65) Prostaglandins
of the E series (PGEltPGE2, etc.) are potent vasodilators.
(Because most assays are unable to distinguish the various
E prostaglandins, they will be referred to as one group-
PGE. ) PGE must exert its effects locally, because of rap
id metabolism in the lungs by 15-hydroxyprostaglandin de
hydrogenase. Up to 90$ is metabolized in one pass. These
two characteristics (vasoconstriction and rapid breakdovm)
make PGE an ideal substance for regulating blood flow with
in an organ.
Autoregulation of renal blood flow by PGE and PGI2 has
been discussed. Like the kidney, the gravid uterus is a
major source of PGI2, PGE, and renin. These compounds could
together regulate uterine blood flow by the same mechanism
as in the kidney. (57.65) Several studies have shown de
creased uterine blood flow in animals given cyclooxygenase
21
inhibitors. (66,67,68)
There have been many reports of PGE levels in peripher
al and uterine venous plasma during normal pregnancy. Re
sults varied in both absolute plasma concentrations and in
relative changes noted throughout pregnancy. (69) Amniotic
fluid levels of PGE have consistently been shown to increase
throughout pregnancy, with highest levels occuring in labor. (69)
If PGE is at least partially responsible for the uter
ine blood supply, a change in its metabolic rate or activ
ity may cause some of the abnormalities seen in preeclampsia.
Some researchers have proposed that a decrease in PGE, with
a relative increase in vasoconstricting PGF2a, may have a
central role in the disease. Speroff (65) proposed the
mechansim shown below (fig. 5)'
degeneration
of
trophoblast
©
I &
liberation
of
trophoblast
uterine ^—
ischemia
renal
glomerular
lesion
protein
uria
v .
renin
angioten
sin©gen
placental
prosta
glandins
angiotensin I
\
angiotensin II
vasospasm g-
hypertens ion ^GFR
adrenal
aldosterone
©
renal
-prosta
glandins
—j>rs odium ^*
reabsorption—oedema
fig. 5« Proposed role of prostaglandins in preeclampsia.
From (65)
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There are several important problems with this mech
anism. 1) PGE has been shown not to cause systemic drops
in blood pressure even upon intravenous infusion of large
amounts. (20) 2) There is a decrease in the renin-aldoster
one-angiotensin system found in preeclampsia that is assoc
iated with edema, not an increase. 3) The changes in the
coagulation system are not included. This mechanism was
proposed before the discovery of TXA2 and PGI2.
There are few reports of PGE measurement in patients
with preeclampsia. Demers and Gabbe (59) measured PGE by
radioimmunoassay in the placental tissues of preeclamptics.
They found lowered PGE and elevated PGF2a, but these lev
els did not correlate with the severity of the disease.
Robinson et al. found that PGE was significantly decreased
in the amnion, chorion, and decidua of women with preeclamp
sia. (70) It is doubtful that the results of these two
studies describe PGE changes due to preeclampsia. They
probably do not reflect prostaglandin levels prior to the
onset of labor, because prostaglandins are known to be in
timately involved in labor. ( 69,70,71)
Another group measured the ability of the placental
vessels to synthesize PGE and PGF. (72) No significant
difference was found between normals and preeclamptics.
Although perhaps not central to the disease process,
PGE may still play an important role in preventing the
uterine ischemia thought to occur in preeclampsia-eclamp-
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sia. The true production rate and effects of PGE in
pregnancy and in preeclampsia remain unclear.
2) Thromboxanes in Pregnancy and Preeclampsia
Changes in vasoconstriction and platelet aggregation
are known to occur in pregnancy and preeclampsia. Since
these are the actions of thromboxane A2 , it is possible
that they could be due to a change in its synthesis and/or
action. In any biological systems in which TXA2 or its
antagonist, PGI2, are implicated, it would be important to
document production or concentrations of both compounds.
An increase in TXA2 throughout pregnancy was measured
by thin layer chromatography, radioimmunoassay, and gas
chromatography-mass spectrometry (GC-MS.) (73) Levels were
shown to double between late pregnancy \i 28-36 weeks) and
term. TXA2 (as determined by its inactive metabolite TXB2)
remained at the same high level during the first stage of
labor, then rose again during delivery. Mode of delivery
did not influence TXB2 concentrations. Preterm labor had
levels consistent with delivery but not with dates. TXB2
levels in preeclamptic women between 28 and 36 weeks gest
ation were not different from those of normal women of the
same gestational age, and did not correlate with platelet
count, factor VIII, or 3-thromboglobulin. (70)
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3) Prostacyclin in Pregnancy
Prostacyclin may have several actions in the maintain-
ence of the altered physiological state of normal pregnancy,
such as maintaining vasodilation, vascular insensitivity to
angiotensin II, increased uterine blood flow, and increased
levels of renin, angiotensin, and aldosterone.
Dose-dependent systemic vasodilation with resultant
decreased blood pressure has been shown with intravenous in
fusion of PGI2. (20)
The insensitivity to the hypertensive effects of angioten'
sin II have been linked to prostaglandins, most likely
PGI2. Dietary deprivation of essential fatty acids in rab
bits during late pregnancy led to increased angiotensin II
sensitivity. (75) Infusion of angiotensin II in pregnant
monkeys or dogs in the third trimester caused increased
prostaglandin release and increased uterine blood flow.
Simultaneous indomethacin infusion reversed these effects
and caused an increased pressor response. (66,68) Preg
nant sheep given indomethacin developed significantly
increased blood pressure and decreased blood flow to the
kidneys, uterus, and the coteledons of the placenta. (67)
Vascular sensitivity to angiotensin II was increased in
normal pregnant women after taking indomethacin or aspirin.
(58) Women taking aspirin regularly during pregnancy were
found to have lov/er birthweight babies and an increased
rate of stillborns compared to those who did not take aspir-
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in. (76) Thus blockage of prostaglandin synthesis is
linked with increased angiotensin II vascular response,
decreased uterine blood flow, and uteroplacental ischemia.
Although PGI2 levels were not specifically measured, it is
known that PGI2 is the major product of arachidonic acid
metabolism in the endothelium, uterus, and kidneys. (44)
Prostacyclin is known to be involved in the renin-an
giotensin-aldosterone system in at least two other ways.
1) Prostacyclin leads to renin release. 2) Angiotensin II
causes prostaglandin release (PGI2 and PGE) from the kidney
and probably the pregnant uterus.
Fossible actions of prostacyclin in normal pregnancy
might then be summarized as in figure 6.
Several groups have measured prostacyclin, or its
metabolite, 6-keto PGFjCt, in tissues of animals having normal
pregnancies ;
Terragno, et al. found 6-keto PGFjii to be the major met
abolite of arachidonic acid metabolism in vascular tissue
from pregnant and nonpregnant cows. (77) Highest levels
were in fetal vascular tissue.
Hamberg et al. found 6-keto PGF^ to be the major
14
product of C-aracidonic acid in isolated human umbil
icial arteries. (78) Human umbilical vessels and placen
tal vessels were shown to have greater PGI2 activity than
vessels from normal adults. (79)
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fig. 6. Possible actions of prostacyclin in pregnancy.
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Homogenates of human cervix were incubated with C-
arachidonic acid. The production of 6-keto PGFjO. (the
major metabolite) was six times greater per net weight in
the ripening cervix than in the nonpregnant cervix. (80)
Plasma levels of 6-keto PGFxa have been reported to
increase during normal pregnancy. Lewis et al. (77)
found significantly higher 6-keto PGF^a in women in late preg
nancy (later than 28 weeks) and in the purperium (less than
7 days postpartum) than in those in early pregnancy (before
twelve weeks) or nonpregnant women. Bolton et al. (81)
measured circulating 6-keto PGFiOt longitudinally in twelve
women throughout pregnancy. They found plasma levels to be
highest at 18 to 22 weeks gestation, then decreased to
early pregnant levels by 34 to 38 weeks. They published
no normal value for nonpregnant women.
One report gives contradictory findings. Ylikorkala
et al. (82) found no difference between pregnent and non
pregnant values of plasma 6-keto FGFiCX, and did not find
any changes with gestational age or other clinical parameters.
All three reports of peripheral 6-keto PGFxa used radioimmuno
assay for detection. It appears that the true changes in
peripheral PGI2 in normal pregnancy, if any, remain unknown.
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4) Prostacyclin in Preeclampsia-eclampsia
A decrease in circulating prostacyclin has been sug
gested as the major pathway for the development of preeclamp
sia by several investigators. (83,84,85) A decrease in
PGI2 during pregnancy, either as the result of vascular
changes in the placenta, or as a primary event, could lead
to the following pathological changes:
1) increased angiotensin II sensitivity
2) decreased renin-angiotensin-aldosterone levels due
to lower PGI2 stimulation of renin production.
3) Decreased blood volume and edema formation due to
hypertension and decreased aldosterone, which lowers sodium
resorption and causes salt and water movement into the extra-
vascular space.
4) higher blood pressure due to both increased angioten
sin II hypertensive effects, and an inbalance in the TXA2/
PGI2 ratio favoring vasoconstriction.
5) decreased renal blood flow and glomerular filtra
tion rate due to local and systemic vasoconstriction and
lowered intravascular volume.
These changes could be represented as in figure 7.
This concept is similar to the "inner vicious circle"
model desribed by Page. (86) In the presence of predisposing
factors (genetic susceptibility, smaller uterine vessels of
the primigravida, multiple pregnancy, hydatidiform mole,
etc.), pregnancy overstresses the ability of the uterine
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fig. 7. Proposed effect of decreased prostacyclin in
preeclampsia.
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vasculature to supply blood to the fetoplacental unit, the
uterine blood supply being regulated by PGI2. Insufficient
blood supply to the placenta causes increased thropho-
blastic tissue and thrombin release, leading to increased
intravascular coagulation, less uterine blood flow, and
eventually the other concomitants of preeclampsia. Once
this positive feedback loop ("inner circle") is started,
it is difficult to stop. The process currently can only
be stopped clinically by removal of the uteroplacental
unit. If the decreased prostacyclin theory is correct,
perhaps the vicious circle may be broken by administration
of prostacyclin, rather than delivery of a pre-term infant.
It is also possible that PGI2 deficiency could be
important only in the most severe cases of preeclampsia -
those fifteen percent with thrombocytopenia. At Yale-
New Haven Hospital in 1980, most of the maternal and peri
natal morbidity and mortality were in women with thrombo
cytopenia. Increased hypercoaguability from a TXA2/PGI2
inbalance could be the operative mechanism responsible
for thrombi formation in diffuse organs. Excessive plate
let consumption may render a patient so thrombocytopenic
that hemostatic mechanisms are compromised. In the hyper
tensive patient, this may predispose her to the develop
ment of intracranial hemorrhage, one of the major causes of
death in preeclampsia-eclampsia.
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Several lines of evidence suggest that a deficiency of
prostacyclin may exist in preeclampsia;
The rate of PGI2 production in umbilical arteries and
placental veins at delivery has been shown to be signifi
cantly lower in preeclamptics than in controls. ( 83,84,85,87,
88) A decrease was also found in other chronic uterine
ischemic states, ( intrauterine growth retardation and essen
tial hypertension. ) Measurement was made with bioassay,
radioimmunoassay, and /or gas chromatography-mass spectrom
etry.
Amniotic fluid in five preeclamptics had significantly
lower PGI2 than in 15 women with uncomplicated pregnancies.
(89) Another study found lower amniotic PGI2 in severe
preeclampsia (N-13) as compared to normal pregnancy (N-27),
but not in mild preeclampsia, diabetes, rhesus-immuniza
tion; or uncomplicated intrauterine growth retardation (IUGR. )
(90) Amniotic TXB2 levels were not different among any
of the groups.
These results indicate a decrease occurs in utero
placental prostacyclin production. To implicate PGI2 as
responsible for many of the systemic manifestations of pre
eclampsia, a decrease in peripheral levels must be shown.
Two case reports have shown PGI2 levels to drop in preeclamp
sia. One longitudinal study showed a precipitous drop in
plasma prostacyclin five weeks before the onset of clinical
preeclampsia in a woman who had had recurrent fetal loss from
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this disease. (91) PGI2 infusion was begun in the woman
when the clinical symptoms of preeclampsia developed. The
blood pressure dropped slighty, and the woman's pulse rose
fifteen beats per minute in response to the drug. Fetal
death occured after four days of treatment. It was thought
by the authors that a PGI2 infusion beginning at the time
of the drop in plasma prostacyclin might have lead to a more
favorable outcome.
The same group treated a 29 year old woman with infusion
of PGI2 for recurrent preeclampsia, after blood pressure
was unable to be controlled by conventional antihyperten
sive medicines. Although plasma 6-keto PGFid levels were
apparenty not measured, the patient responded to the drug
with a dramatic decrease in diastolic pressure (from 140
mm Hg to 80 mm Hg. ) Three episodes of fetal bradicardia
lasting one to two minutes each occured on the fourth day
of PGI2 administration, so the fetus was delivered by cesear-
ian section at 27| weeks. When the infusion was moment
arily stopped for indution of anesthesia, the patient's blood
pressure rose to 200/110 mm Hg. After the infusion was re
started, the blood pressure returned to 130/80. The infant
has since done well. (92)
Remuzzi et al. (93) noted a decrease in a poorly defined
"prostacyclin stimulating factor" in late normal pregnancy,
but saw an increase to the nonpregnant values in preeclampsia.
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The only published study of maternal plasma 6-keto PGF1a
in preeclampsia (94) found no differences in these levels
in preeclamptics women (266.4 pg/ml) versus normals (267.0
pg/nl), or those with other complications of pregnancy
(diabetes, twins, premature labor, bleeding, IUGR).
However, this study is from the same group that found no
difference in plasma 6-keto PGFaa levels in preganat women
versus nonpregnant women. (82) There are several problems
with the study itself. Their measurement technique (radio
immunoassay) was never verified by gas chromatography-mass
spectrometry, or any other methods. Thus the method may be
so nonspecific that changes in actual 6-keto PGFxa may be
masked. A biological blank was never described (see next
section). Participant selection was questionable. "Pre
eclamptics" were defined as those patients with blood pres
sures over 140/90 mm Hg. No consideration was given to
proteinuria, edema, or coagulation changes. Whether
patients with essential hypertension or superimposed pre
eclampsia are included in the group is not specified.
These flaws, and the fact that only one study measuring
6-keto PGFiCt in preeclamptics has been reported to date,
make it important to repeat the study.
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III. Purpose of Study
The possibility that there is decreased prostacyclin
(PGI2) production and action in preeclampsia-eclampsia is
currently being examined by several laboratories. Beacuse
of prostacyclin's various actions (vasodilation, platelet
aggregation inhibition, and possible role in the renin-angio
tensin-aldosterone system), an increase in the peripheral
activity of this chemical could explain much of the altered
physiology of normal pregnancy. A relative decrease in per
ipheral and local activity could theoretically tie together
the various pathophysiological findings of preeclampsia.
Therefore, 6-keto PGFiOC, the stable nonenzymatic met
abolite of prostacyclin, was measured in the plasma of women
with and without preeclampsia, to determine if there were
any changes in peripheral concentrations of the chemical in
these conditions.
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IV. Techniques for Prostacyclin Measurement
There are four major techniques for prostacyclin
measurement ( and for all prostaglandins ) (42,43) :
D Gas Chromatograhy-Mass Spectrometry (GC-MS) Sen
sitive, specific, and definitive, but also time consuming
and requiring expensive, delicate equipment that is not
available to all investigators. It is the standard to
which other methods are compared.
2) Radioimmunoassay (RIA) 6-keto PGFjd, the stable non-
enzymatic metabolite of prostacyclin, is detected. The
method is extremely sensitive (to the picogram range) but
is hampered by a lack of specificity. Relatively inex
pensive and simple.
3) Bioassay Less sensitive and less specific, it was
the original detection method for both TXA2 and PGI2 before
their chemical structures were known. This is the only method
that detects prostacyclin directly, instead of its metabolite.
Two different types of assay are used:
superfusion bioassay - Blood is withdrawn from an animal
by a pump, run over three isolated assay organs, and return
ed to the animal. Smooth muscle relaxation is correlated
with prostacyclin concentration.
platelet aggregation inhibition bioassay A biological
sample such as citrated plasma is added to platelet-rich
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plasma. The sample's ability to inhibit ADP-induced
platelet aggregation is measured spectrophotometricly.
(95) Calibrated by CG-MS , inhibition can be used to
measure prostacyclin activity. Assurance that PGI2 is the
active substance is made by demonstating its stability at
0 C and basic pH, but not at physiologic conditions.
4) C-Arachidonic acid Incorporation - Chromatography
Used to measure the ability of a tissue to produce prosta-
14
cyclin. C-aracidonic acid is added to a washed tissue
sample and incubated. The radioactive products are sep
arated by chromatographic isolation and the relative amounts
of each product are measured with a scintillation counter
Radioimmunoassay and bioassay are the common and most
practical methods for prostacyclin measurement. Bioassay
has been used for a longer time, but has the disadvantages
of lack of sensitivty, lack of specifity, and the need to
run each sample immediately after it is obtained. RIA was
chosen for experimental PGI2 determinations in this study
beause of its availability, relative simplicity, low cost,
and sensitivity.
A. Radioimmunoassay
The basis of RIA is competitive binding of labeled and
unlabeled antigen to a specific antibody. Unlabeled anti
gen (the sample) is mixed with labeled (radioactive) anti-
gan. The two are allowed to react with a limiting and con-
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stant amount of specific antibody. As the amount of un
labeled antigen is increased, less binding of the labeled
antigen occurs. Bound (antigen-antibody complexes )antigen
is commonly separated from the free antigen by adsorption
of free antigen onto activated charcoal. The charcoal is
then removed by centrifugation.
The radioactivity of the antigen-antibody complexes is
measured. A standard (dose-response) curve is made by
assaying known amounts of the substance. The amount of
antigen in each unknown sample is interpolated from the
dose-response curve. (96)
For the particular assay used in this experiment, the
antigen was 6-keto PGFja, The labeled antigen was ^H-6-keto
PGFiO.. Radioactivity was measured by adding phosfluor-
escence coctail that releases photons when hit by 3 parti
cles from the radioactive antigen.
The major problem with RIA is lack of specificity.
This is caused by nonspecific binding of other substances
by the antibody. In prostaglandin assays, this could be
due to other prostaglandins, related chemicals (such as
fatty acids) or to unrelated compounds. The techniques of
sample collection and purification can greatly affect the
amount of materials that may bind nonspecificly to the
antibody, and so are critical to the assay.
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2) Sample collection
All researchers using the 6-keto PGFxa RIA in plasma
agree that blood samples must be collected in cold tubes
or syringes containg anticoagulant and a cyclooxygenase in
hibitor to stop further arachidonic acid metabolism. Some
workers use heparin (97,98,99) but others use EDTA (ethyl-
enediaminotatraactetate ) as an anticoagulant. (81,100)
Heparin has been reported to cause falsely elevated values
for the 6-keto PGFjCt measurement due to inhibition of anti
gen-antibody binding. (96,100) Indomethacin is the most
commonly used cyclooxygenase inhibitor, but aspirin, al
though less potent, has been shown to have comparable re
sults.
Samples are then quickly centrifuged. The plasma is
removed and stored at -20 ~C. No data is available on the
length of time that a sample maybe stored without changing
its binding characteristics, but most papers specify that
samples were assayed within a month of collection.
3) Sample Purification
Considerable controversy exists over the need to pur
ify a plasma sample prior to RIA.
When RIA of a new arachidonic acid metabolite is be
ing developed, purification by several steps has been
traditionally been used to remove any other materials
that might bind to the antibody. Purification by extrac-
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tion to remove more polar chemicals, followed by silica
gel column chromatography and sometimes high pressure
liquid chromatography (HPLC),has been used. (101,102)
HFLC has been shown to be unnecessary for use with
the RIA of several prostanoids. (102) and was not used in
any of the reports descibing 6-keto PGFid in plasma.
Silica gel column chromatography theoretically would
improve specificity by removing most of the other prosta
glandins. However, preliminary studies done during this
project showed that not only was 30 - kOfo of the 6-keto
PGFjtx lost during this step, but the solvents used in
the procedure (especially benzene) contained material which
cross-reacted with the antibody, causing falsely elevated
measurements. This result was confirmed by Hall. (103)
Most often, extraction is the only purification
procedure considered necessary. Extraction is done to dis
sociate prostacyclin from, albumin, remove polar substancer,
and to concentrate the sample so that lower concentrations
of the compound may be detected. But several groups have
found that extraction adds more impurities to the sample.
(96,104) Morris, Sherman, and Sheppardson (100) noted that
when samples derived from comparable volumes of reagent
blanks were assayed with diethyl ether, ethyl acetate, or
chloroform, RIA measurements were greater than those of
unextracted plasma. Mitchell (106) found that ethyl acetate
extraction of acidified samples caused the formation of
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"3 or 4 other compounds"- most of which reacted to the
antibody. One group, which used ethyl acetate extraction,
reported water and buffer blanks of 7.8pg/ml by assay.
However, it is unclear whether these blanks were subjected
to the extraction procedure. (97)
Because of these difficulties with plasma purification
techniques, several groups suggest that plasma may be direct
ly assayed. (96,100,104) This approach would require the
development of a "biological blank. "
Samples must be in the same milieu as the standards
to which they are compared. Extracted samples are recon
stituted in buffer. Controls and standards are in buffer.
If samples are not extracted, the controls and standards
must be in the same biological matrix (plasma), but this
matrix must not contain any 6-keto FGFjtx or cross-reacting
materials. Attempts have been made to prepare this "biol
ogical blank" without success. (96) Morris et al. (100)
have used the plasma from subjects treated with I800mg of
aspirin a day for 3 days. No mention of the plasma blank's
actual measurement by RIA was made. Hall described charcoal
stipped plasma blanks reading 40-50 pg/ml. (103) Mitchell
tried removing cross-reacting substances several ways; feed
ing plasma donors aspirin for several days before sampling,
treating plasma with charcoal before use, dializing the
plasma, and precipitating out the 6-keto PGFjii with a spec
ific antiserum. All of these techniques changed the bind-
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ing characteristics of the plasma used for the biological
blank, and lead to negative values for plasma samples com
pared with standards made up in the treated charcoal.
It appears that all of the methods of sample prep
aration have serious drawbacks that have not been over
come.
4) Assay Verification
It is important to validate the results of radioimmuno-
asay by several parameters.
l)Specificity This is determined by the cross-reacting
compounds and by nonspecific binding to the antibody. The
latter is difficult to determine, but may be approached by
measuring blanks of different solvents used in the assay.
Cross-reactivity is calculated as:
amount of specific antigen for 50$ displacement
cross-reacting substance needed for displacement
2) Sensitivity Three definitions are commonly used-
i) the amount of antigen needed for a certain percentage of
displacement of the labeled antigen (50$ displacement, or
mass for logit=0, is commonly quoted), ii) slope of the
dose response curve, and iii) "least detectable mass"-
mass resulting in a response two standard deviations from
the blank's value.
U2
3) Precision How closely repeated measurements of the
same sample agree. The coefficient of variation is often
used as an index of precision.
coeffitient
_, „ _,
0f _ standard devation ^ 10Oft
variation
~
mean of samples
4) Accuracy How close the measured values are to the
actual value. This can be assessed in two ways - i) meas
urement of the samples by an independent method, such as
GC-MS. ii) Assaying known concentrations of standard and
comparing the assay result with the known amount.
5) Parallelism Each sample must, on dilution, yield
a curve that is parallel to the standard curve. This test
can be done with the test for accuracy. A known amount of
antigen can be serially diluted, and the slope of the line
of measured vs. known amounts calculated.
Without these verifications, the data cannot be con
sidered reliable. Even if all the tests done within an assay
are acceptable, the data could still be misleading. For
example, a substance may have low cross-rectivity, but if it
is at very high concentrations compared to the antigen, it
would have a significant effect on the assay. Thus it is
important each time an assay is developed for a biological
system such as plasma, that confirmation be made by another
43
method, preferably gas chromatography-mass spectrometry.
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V. Materials and Methods
Plasma 6-keto PGFjO. was measured by radioimmunoassay
in women with preeclampsia-eclampsia, and in women having
uncomplicated pregnancies (controls). Two studies were
done. Study I had samples from 14 preeclamptic women and
46 controls. All samples were extracted with ethyl ace
tate. In study II, samples from five preeclamptics and
24 controls were prepared by different methods- ethyl
acetate exraction, solid phase extraction, and no extrac
tion.
A. Materials
Indomethacin - Merk, Sharp, and Dohme Research Laboratory,
Rahway, New Jersey
Ethanol - 200 proof, Pharmco. Publicker Industries Co.
Linfield, Pensylvania
ethyl acetate - spectrophotometric grade, Mallinckrodt ,
Paris, Kentucky 40361
methanol - spectrophotometric grade, Mallinckrodt,
Paris Kentucky 40361
acetic acid - Fischer Scientific,
Fair Lawn, New Jersey 07410
trimethylpentane - Spectrophotometric grade, Mallinckrodt,
Paris, Kentucky 40361
Phosphomolybdic acid - 3*5$ in isopropanol - Brinkmann Inst,
Westbiy , N.Y. 11590
Hydrochloric Acid - J.T.Baker Chemical Company
Phillipsburg.New Jersey 08865
Sodium phosphate monobasic - Mallinckrodt,
St. Louis, Missouri 63164
Sodium Chloride - Fischer Scientific
Fair Lawn, New Jersey 07410
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Sodium Phosphate Dibasic Heptahydrate - Mallinckrodt,
St. Louis, Missouri 63147
Sodium Azide - Mallinckrodt,
St. Louis, Missouri 63147
Gelatin - Matheson, Coleman, and Bell
Norwood, Ohio 45212
Picofluor scintillation solution for aqueous samples,
Packard Instrument Co. Downers Grove, Illinois 60515
Quantagram thin layer chromatography plates, 5X20 cm
Quantum Industries Fairfield, New Jersey 07006
Isocap Liqiud Scintillation Ssytem , Chicago Nuclear
Chicago, Illinois
Hewlet Packard 9866 minicomputer,
Loveland, Colorado 80537
Heparinized vacutainer tubes, 10 ml - Becton-Dickinson,
Rutherford, New Jersey 07070
Charcoal, Norit A - Fischer Scientific Company,
Fair Lwan, New Jersey 07410
Dextran T70, Pharmacia,
Uppsala, Sweden
Water soluble silicone, Siliclad - Clay Adams
Pasippany, Pennsylvania 07054
Borosilicate glass test tubes, 12v75 - Scientific Products
- Fair Lawn, New Jersey 07410
•^H-6-keto PGFjCt , in acetonitrile/water 9sl» New England
_ Nuclear, Boston, Massachusetts 02118
^H-TXB., (5,6,8,9,11,12,14,15 3h-TXB2, in ethanol, New
England Nuclear, Boston, Massacusetts 02118
TXB2 and 6-keto FGFiOC antisera were provided by
Dr. Harold R. Behrman, Professor,Obstetrics and Gyne
cology and Pharmacolgy, Yale University School of
Medicine New Haven Connecticut 06520
B. Methods
Participant Selection All women who were admitted to the
Yale-New Haven Hospital labor and maternity floors with the
diagnosis of preeclampsia-eclampsia or hypertensive dis
ease of pregnancy were eligible for the study. Participants
were selected between November 4,1981 and February 20,1982.
Pertinent clinical data was recorded to verify the diagnosis
of peeclampsia-eclampsia or superimposed preeclampsia.
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Control blood samples were obtained from pregnant women of
various gestational ages at the YNHH Women's Center. In
both preeclamptics and controls, the participants* permis
sion was obtained according to the Human Investigation
Committe Protocol.
Sample Collection ten- ml blood samples were taken by veni
puncture using a tourniquet into ice-cold heparinized
vacutainer tubes containing one microgram of indomethacin.
The contents of each tube was gently mixed, immediately placed
on ice, and transported to the laboratory (approx. 3 minutes.)
Tubes were then centrifuged at 2000xg for 10 minutes at 4"C.
Two 2 ml aliquots of plasma were then pipetted off, care
being taken not to disturb the buffy coat. Approximately
2000 cpm of purified ^H-6-keto PGFjd and ^H-TXB2 in C.2 ml
of Buffer L (described below) were added to each sample
for recovery determination. Then each sample was vortexed
and stored at -20 C until assay.
Purification of Tritiated Tracers For each tracer, 100.1
of trace in ethanol or acetonitrile/water, and 100 ^1 of
nonradiocative standard were then each evaporated under
N2, and resuspended in 50/1 of 2:1 chloroform:ethanol.
Standard and tracer were spotted on separate columns of
the same silica gel thin layer (TLC) plate, and chromato-
graphed in a mixture of 22:4:10 ethyl acetate : acetic acid:
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trimethylpentane. The TLC columns were separated, and
the column with the standard was developed by spraying
with 3.5?° phosphomclybdic acid and heating until the
standard became visible. The corresponding segment of
the column containing tracer was collected into a fiber
glass-stopped pipette, and the tracer was eluted with
ethanol.
Preparation of Solvents and Buffers
Buffer L ( Na2HP04'H80, 0.538 g/l ;Na2HP0v ?H20 ,1. 635
g/1; NaN~ lg/l ; NaCl, 9g/ls and gelatin, lg/l) was used
as the diluent for the recovery tracers.
Charcoal with fines removed was prepared by vigorous
ly mixing 20 g Norit A charcoal with 200 ml distilled water
in a graduated cyllinder, then allowing the mixture to
settle. The fines were removed from the top of the water
by adsorption onto paper towels. The water was decanted,
and the charcoal dried overnight.
Dextran Coated Charcoal was prepared by suspending
0.5 g clarcoal with fines removed and 50 micrograms Dextran
T-70 in 200 ml buffer L.
Preparation of plasma controls Charcoal-treatin plasma
should remove all prostaglandins and so allow a standard curve
and biological blank to be made from it, but it is possible
that this step might alter the binding characteristics of the
plasma. Therefore, plasma standards were made up in both
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charcoaled and uncharcoaled plasma. For charcoaled plasma,
250 ml of human plasma was obtained from the Blood Bank.
Charcoal with fines removed was added to make a 5f° w:v sol
ution. The mixture was mixed at 37 C for two hours, then
centrifuged at 2200 rpm for fifteen minutes. The supernat
ant was filtered through a buchner funnel with filter paper
to remove any remaining charcoal.
Using both charcoaled and uncharcoaled plasr.ia, two
sets of control plasma standards were made. In each,
6-keto PGFxa was added to an aliquot and serial dilutions
made for final concentrations of 2000,1000,500,250,125,
62. 5, and 0 pg/ml of added antigen.
Sample Preparation
Two studies were done. In the first, all samples were
prepared by liquid/liquid phase (ethyl acetate) extraction.
The assay was run in borosilicate glass test tubes. In
Study II, samples from each patient and all standards were
prepared by three methods - solid phase extraction, liquid/
liquid phase extraction (with ethyl acetate) and using no
extraction. Siliconized test tubes were used.
Liquid/liquid Phase Extraction 2 ml plasma samples,
with recovery added, were thawed and acidified to pH 3-5
with 0.1 ml of 1.0 N hydrochloric acid. Eight ml of re
distilled ethyl acetate were added, and each sample was
shaken by hand for five minutes. The phases were separated
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by centrifugation at 2200 g and 4 C for 10 minutes. The
upper phase was pipetted off and dried under Np in a small
scintillation vial at room temperature. The sample res
idues were resuspended in 2.0 ml ethanol and stored at
-70 C until assayed.
Solid Phase Extraction C,p silica cartriges were at
tached to disposable syringes, and activiated by passing
2xi ml of methanol, then 3*1 ml of distilled water through
the cartriges. Residual fluid was removed by forcing air
through with the syringe between each addition step. The
2 ml plasma sample with recovery trace was added to the
cartrige and allowed to go through. Residual sample was
removed with air. The column was washed with 2x3 ml of
distilled water, and the prostaglandin-containing fraction
was eluted with 2x0.5 ml of methanol.
Siliconized test tubes were used for the second study.
Borosilicate glass test tubes were immersed for 5 seconds
in a 1:100 solution of water soluble silicone, then thor
oughly rinsed first in tap water, then distilled water,
and allowed to dry.
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6-keto PGF,g Radioimmunoassay
The assay was performed according to the New England
Nuclear RIA kit instructions, except that unsiliconized
tubes were used for study I. Treatment of extracted and
unextracted samples were slightly different.
Procedure for extracted samples
Standards of 1000, 500,250, 100, 50, 25, and 10 pg/0.1 ml
of kit buffer were freshly diluted just prior to assay-
Then 0.1 ml of each standard was aliquoted in triplicate
into assay tubes. One ml of each extracted unknown sample
and plasma standard was aliquoted into an assay tube and
dried down under air at room temperature. 0.2 ml (or ten
percent) of each sample was stored in a scintillation vial
for later estimation of recovery. Total count (s), zero
added mass (0) and blank (Oab) tubes were prepared. Re
agents were added to the tubes as follows:
buffer tracer antibody
s 900^- 100yO - /tj.
OAb 400 100 -
0 300 100 100
Standards 200 100 100
Plasma controls 300 100 100
Samples 300 100 100
Thus all tubes except s had a final total volume of 500
microliters. The tubes were vortexed for 5 seconds each
and allowed to incubate for 16 hours at 4 C.
After incubation, all tubes were placed in an ice
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bath for ten minutes. 500 microliters of iced charcoal
suspension were added to each tube except s within one min
ute. All tubes remained in the ice bath for an additional
fifteen minutes, and then was centrifuged at 1000 g at 4 C
for 10 minutes. The supernatant fraction was decanted into
scintillation vials using consistent technique. 3*5 ml of
Pico-Fluor scintillation cocktail was added, and the mixture
was vortexed for 2-4 seconds. The samples were then
put in the scintillation counter for radioactivity measure
ment.
Procedure for Unextracted Samples
Because the unextracted samples were in plasma rather
than buffer, standards could not be in buffer. There
fore, all standrds were freshly made up in charcoaled
plasma. 0. 6 ml of each unknown sample and each plasma
control were aliquoted into an assay tube. s, OAb, and 0
tubes were prepared. Reagents were added to the tubes as
follows :
buffer tracer antibody
s 1200A? 100^ - mX
OAb 700 100
0 600 100 100
Standards 500 100 100
Plasma Controls - 100 100
Samples - 100 100
Thus all tubes excet s had a final volume of 800 microli-
ers. The rest of the procedure was unchanged.
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C. Calculation of Results
All calculations were made using the Hewlett Packard
9380 minicomputer and a previously prepared program. (107)
The standard curve was obtained from the standards in
buffer using weighted linear regression analysis and the
logit/ln transformation of Rodbard. (108)
A scatchard plot of bound/free vs. bound, or
&7^
logit-log( /-iv /v ) vs. In (dose of standard in pg)
o
was automatically printed. The weighted linear regres
sion line was calculated between the lowest linear dose and
the dose just producing over logit-0 displacement (or 50/«
displacement of th tracer). The slope of this line affin
ity.
The transformation yields a straight line defined by
the equation:
ln(dose). (affinity)* log( 1_^n— ) - ln(mass for logit=0)
fo Recovery was calculated from C (the cpm of the 10$ al
iquot of the sample *10) as:
a
C
,o recovery - t0^a]_ Cpm added for recovery determination
Calculation of Unknowns was determined from the standard
curve transformation by the computer program, which auto
matically corrected for the mass and added counts of the
recovery tracer,. Total corrected count, corrected B , and
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corrected logit were calculated as follows:
corrected total - s - C F
corrected B - ((total count )/s)*B
corrected OAb : (blank)- ( (OAb-background)*corrected total
- background
B - cpm in assay tube - corrected OAb
™vv^~+«,q i~,rn+ iv, (B/corrected Bn)corrected logit - In 7-i—£-7 . ,—SH-vto (1-b/corrected B0)
where s - counts per minute (cpm) of the s tubes
C - cpm in recovery vail * 10
F - decimal fraction of the sample aliquoted into the
assay tube
B - cpm in the zero added mass (0) tube, corrected for0
Oab
OAb - cpm in the zero antibody (OAb) tubes
All values are in counts per minute (cpm) and corrected for
background (cpm measured when empty vail is counted).
From the corrected logit, the total mass was deter
mined by interpolation of the logit/ln transformation.
Correction for systemic error due to mass added with recov
ery tracer was computed as follows :
, „
total cpm of tracer , n „^
corrected mass - measured mass - specifr£ activity *CE 100$
where CE - counting efficiency of the scintillation counter,
The specific activity of the tracer is in dpm/pg.
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Statistical Analysis The statistical significance of the
difference in plasma 6-keto PGFjd between two clinically
defined groups was found by the Student's t test:
S ,2) - Hx,2;
x \l (Nj + N2 - 2)
'd-= r(*a ) Hx-,^) -^NxP - Nx, / _L - _L
t = Xj. - x.
sd-
X
whGrs S
dx is the standard error of the difference of the
means, Nx - the number of data points for group 1, N2 = the
number of data points for group 2, and Xj and x2 are the val
ues of 6-keto PGFxa for gropus 1 and 2, respectively.
For testing ths significance of the pearson product-
moment correlation between two variables x and y, the fol
lowing equations were used:
r =■ mrx - N2XY-iN2X2Y
rY
CNe>X: - UXPJV, /N2Y3-(ZY)2)'/z.
where r - correlation coefficient,
N =" the number of paired data points
m - the slope of the correlation line
r- - the standard deviation of the x values
x
rr - the standard deviation of the y values
The statistical significance of t for degrees of freedom(N-2)
was found in a standard statistics text. (109)
55
VI. RESULTS
A. Assay Parameters for Study I.
Study I. All samples prepared by ethyl acetate ex
traction.
$BQ (Binding with no unlabeled antigen) - 42.2$
Correlation of logit vs. In dose r - O.985
Specificity Cross-reactivity of some related compounds
(data from New England Nuclear Corporation):
6-keto PGFxa 100$
PGF2a 2.7$
PGE 2 2. 0$
TXB2 0.1$
PGA2 0.1$
PGAa 0.3$
Nonspecific binding of assay solvents and blanks:
Substance "6-keto PGF,q"
ethanol 2 ml 12.0 pg/ml
ethyl acetate 8 ml 10.4
HC1 0.1 ml 1.6
distilled water 0-2.1
distilled water 84-97.8
(extracted)
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Sensitivity - Study I.
l)Mass for logit-0 (mass needed to displace 50$ of the
labeled antibody - 199 • 6 pg
2) "Least detectable mass" (mass resulting in a response
2 standard deviations away from the response to a zero
dose) - 110.4 pg
Precision and Accuracy
Serial dilution o f standards (extrac:ted) :
Amount of
6-keto PGFja
added to
solvent
pooled
plasma
as solvent
distilled
water
as solvent
0 pg/ml 65 pg/ml 97.8 pg/ml
0 73 84
0 62 -
62.5 93 -
125 74 176
250 - 276
500 70 457
1000 93 529
2000 151 1398
r2- 0. 814 r2 - O.963
y-intercept - 68 y-intercept - 89
Kit Controls (specially treated plasma with either
0 or 1000 pg/ml) :
extracted unextracted
0 pg/ml 284 pg/ml 0
1000 pg/ml - 1223
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Study I.
Serial dilutions of standards (unextracted):
Amount of measured
6-keto PGFaa 6-keto PGFjOt in
added to pooled plasma
pooled plasma solution
0 pg/ml 58 pg/ml
0 74
0 66
62.5 105
125 139
250 198
500 286
1000 663
r2 - 0.9623
y-intercept - 89
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Plasma 6-keto PGFxa Values (continued)
gestational platelet plasma
patient # age
20
age count 6-keto FGF,
np29 _ 174
np30 21 10 - 117
np31 38 36 - 212
nP32 23 36 - 237
nP33 22 30 - 148
nP34 19 21 - 164
nP35 26 24 - -
np36 25 32 - -
nP37 31 - - -
nP38 19 35 - -
nP39 30 35 - -
np40 19 37 - 217
np4l**** 19 32 - 193
np42 18 37 - 223
np43 21 36 - 280
np44 41 36 - -
np45 19 36 - 348
np46 19 22 - 161
mean - 163
S.D. - 58
***
- twin gestation
*** - eclampsia
*» _ severe preeclampsia
* - chronic hypertension
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Study II.
A. Assay Parameters
$B (Binding with no antigen) - 41.6$
Correlation of logit vs. In (dose) r2 - O.96I
Specificity Cross-reactivity is the same as in study I.
Nonspecific binding of blanks:
liquid- solid
liquid phase without
extraction extraction extraction
stripped 64 * *
plasma * - 196
*
- 218
distilled 450 2-? *
water 91 * *
94 29 5 ■w-
Sensitivity
1) Mass for logit - 0 (mass needed to displace 50$ of
the labeled antibody) - 154.8 pg
2) "Least detectable mass" (mass resulting in a re
sponse two standard deviations from the response
to a zero dose) - for liquid/liquid extraction,
211 - 2* 292 - 795 pg
Not determinable for SFE or nonextracted blanks.
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Study II.
Precision and Accuracy
Measured and actual amounts of 6-keto PGFjCX in serial
solutions of plasma and water were compared:
Amount of Measured values in samples treated by:
6-keto PGFjti ethyl solid
added to acetate phase no
solvent extraction extraction extraction
solvent- charcoal-stripped plasma
0 pg/ml
0
0
62
62
125
250
500
1000
2000
2003
64
*
*
*
*
55
95
196
219
283
255
237
270
345
339
66
^394
solvent - distilled water
rs - 0.205
y-intercept - 1±7
slope-0.64
0
0
0
62
62
125
250
500
1000
2000
2000
450 27 *
91 295 *
94 - «
95 80 159
120 - 150
» 50 127
15 161 490
254 161 490
256 244 699
359 175 1159
_ - 3319
r2 - 0. 239 r2 - 0. 235 r2 - 0.738
y-intercept y-intercept y-intercept
- 127 - 106 - -20
slope-0 .11 slope-0 .06 slope - 1.08
♦ - negative value
- - no data available
Study II.
Plasma 6-keto PGFjd va
gestati
patient age age
controls :
50 35 9 wee
51 19 25
52 18 -
53 19 16
54 26 18
55«* 20 36
56 23 -
57 20 -
58 24 -
59 23 16
60 18 35
61 22 33
62 24 36
63 24 -
65 26 18
66 23 8
67 19 23
68 25 -
69 26 34
70 19 37
71 19 16
72 23 34
73 22 32
74 19 -
** twin gestation
* uninterpre table (
_ no data available
6-keto
platelet ethyl
count acetate
- 55
230,000 301
- 102
- 116
- 151
220,000 180
- 92
- 122
- 89
190,000 93
200,000 56
180,000 364
180,000 101
- 140
210,000 89
240,000 97
220,000 111
- 176
260,000 133
190,000 100
360,000 103
190,000 37
190,000 -
- 129
mean 130
gative ) values
Study II.
Plasma 6-keto PGFid values:
6-keto
gestational platelet ethyl
patient age age count acetate
preeclamptics :
64 17 29 60,000 *
016 19 33 200,000 -
017 18 28 65,000 61
018 25 39 150,000 72
019 32 31 110,000 9?
mean - 75
longitudinal study of a preeclamptic:
015 33 31 1/24 140,000 129
1/26 180,000 124
1/27 210,000 -
1/28 250,000 124
1/29 250,000 *
1/30 240,000 129
1/31 240,000 130
2/1 250,000 113
2/4 - 105
2/11 - 130
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C Correlation of 6-keto PGFjd with Clinical Findings
In study I, the correlation between 6-keto PGFjCt and
platelet count in preeclamptics (r=0.73) was found to be
statistically significant, as was the correlation between
6-keto PGFjtx and gestational age in the controls (r*0.285,
p 0.05) The difference in 6-keto PGFjCX in preeclamptics
(N=Q) and controls (N=15) in the twenty seventh week of
gestation and beyond was not stasticically significant.
The correlation of 6-keto PGFxa and systolic blood
pressure, diastolic pressure, maternal weight, infant
weight, and maternal age was not significant. 6-keto
PGFjd levels were not different between primiparas and
multiparas in the control group. All preeclamptic
women were primiparas except one with a history of preeclamp
sia in previous pregnancies.
1) 6-keto PGF,a vs. platelet count in preeclamptics
r = 0.7333 N
- 11 t ="3.235 0.05>p>0.01
2) 6-keto PGP^ vs. Gestational age in controls
r = 0.285 N - 31 t -= 2.118 0.05>p>0.01
3) 6-keto PGF-,01 vs. gestational age in preeclamptics
r = 0.189 N = 12 t = 0.751 N.S.
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3) 6-keto PGF,g vs. systolic blood pressure in controls
r —O.319 N = 30 t = 1.783 N.S.
4) 6-keto PGF,g vs. diastolic blood pressure in controls
r --O.H889 N - 37 t = 0.749 N.S.
4) 6-keto PGF-,g vs. maternal weight in controls
r - 0.859 N = 24 t = 0.787 N.S.
5) 6-keto PGF-,q vs. infant birth weight in all
r = 0.277 N - 17 t - 1.074 N.S.
6) 6-keto PGF-,a vs. maternal age in controls
r = 0.049 N - 35 t - 0.282 N.S.
7) 6-koto PGF-,q in primiparous vs. multiparous controls
nulliparas N = 12 multiparas N = 18
x « 165 pg/ml x ■= 155 pg/ml
SD =• 23.96 t = 0.004 N.S.
x
8) 6-keto PGF,q in preeclamptics vs. controls
preeclamptics N = 9 controls N = 15
x =■ 149 pg/ml x = 191 pg/ml
S.D.- 70 pg/ml S.D.- 73 pg/ml
SD - 35.31 t = 1.189 N.S.
x
N.S. - not statistically significant
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VII. Discussion
1) Validity of Data
The data from the two studies must be considered
unreliable because of the inability to show appropriate
results with the measurements of the serial dilutions of
standards.
In study I, the extraction procedure appeared to in
troduce antibody-reactive material. Significant 6-keto-
PGFxq was measured in distilled water blanks that were
assayed after extraction (90 pg/ml) as compared to water
blanks that were assayed without extraction. (0-2 pg/ml)
The solvents used in the extraction were each tested indi
vidually, and the low measured values could not totally
account for the high water blank.
The results of measurements of serial dilutions of
known amounts of 6-keto PGFxq in both pooled plasma and
distilled water were done to assess the accuracy and par
allelism of the system. The standards added to water
which were then extracted showed fairly good correlation
between measured and actual values, despite a high blank
(90 pg/ml. ) The standards in pooled plasma that had been
6B
extracted with ethyl acetate showed poor correlation with
actual values. Throughout the dilution range (0-2000 pg/ml),
the measured values were fairly constant (65-151 pg/ml).
This could be due to several factors: i) The extraction may
have broken down added 6-keto PGF^ into antigenicly unreact-
ive components, or ii) the ethyl acetate may not extract all
of the unphysiologically high amounts of the 6-keto PGFaq
from the aqueous phase of the plasma.
All samples in Study I were extracted with ethyl ac
etate. In view of the poor results fron extracted standards in
plasma, the data from Study I cannot be considered reliable.
As part of Study I, a set of plasma standards which had
not been extracted was assayed. The correlation between
measured and actual concentrations was much better (r2= O.98,
slope - 0.57) than the correlations of the extracted plasma
samples (r2- 0.81, slope - 0.03). Because of the high
blanks and poor results in the plasma that had been extract
ed compared to those without extraction, it became clear
that the extraction process itself caused a significant
lack of precision and accuracy.
Thus to determine which method of preparation leads
to the most precise and accurate results, Study II was done.
Each control, and most samples in this study, were pre
pared in three different ways
- ethyl acetate extraction
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(liquid/liquid phase), solid phase extraction (SPE), and
no extraction.
Blank values in the second study varied greatly, from
negative values to 450 pg/ml. Correlations between measured
and actual values of standard dilutions for both ethyl acetate
extraction and no extraction were much worse than the same
experiments done in Study I. Correlations for standards
treated with solid phase extraction were equally poor. For
all three methods, many of the results were uninterpretable
because the radioactivity of the bound antigen in the sample
were higher than that of the zero tubes (those with no
added sample. ) This means that negative values for 6-keto-
PGF1a were obtained.
It is apparent that the assay itself did not work
appropriately in Study II. The standard curve in buffer,
used to determine the dose-response curve, was not acceptable,
as shown below.
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fig. 10. Dose-response curves for Studies I and II.
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This failure of the assay in Study II could be due to
several factors:
i) Error in experimental technique. Although conditions
for the assay ( treatment of reagents, pipetting technique,
equipment, incubation period, and charcoaling technique)
were kept as constant as possible, errors in performing the
assay could not be ruled out.
ii) Siliconized test tubes. In study I, the test tubes
for the assay were unsiliconized borosilicate glass. Test
tubes for Study II were siliconized according to the NEN assay
kit instructions. This was to decrease the amount of 6-keto
PGF^ that adsorbed to the glass. The siliconizing agent
or the method used may have altered the assay.
iii) Reagent Instability. Reagents had been refriger
ated at 4"C for an additional month for Study II. Although
lyophylized reagents were not reconstituted until the evening
that the assay was performed, it is possible that the reagents
may have been unstable. The charcoal was supplied as a sus
pension in phosphate buffer, and was reported to be stable for
two months. There was a six week period between obtaining
the suspension and running the assay for Study II.
It was hoped that Study II could suggest which method of
sample preparation led to the most accurate results, and would
also provide more data on 6-keto PGFxq in the plasma of nor
mal and preeclamptic women. However, with the study itself
being unreliable, conclusions cannot be drawn from this study.
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2) Correlation of 6-keto PGFiq with Clinical Results
It is tempting to accept the data on plasma 6-keto FG'f\a
obtained from Study I, despite the problems with verifying
the assay's validity. Although there was poor correlation
between measured and actual values in plasma samples spiked
with various amounts of synthetic 6-keto PGFjq, the correl
ation is fairly good for water spiked with 6-keto PGFjq.
More interestingly, the values found in plasma agree with
previously reported results. Mean levels of 6-keto PGFjq were
low in early pregnancy (135 pg/ml), increased in mid preg
nancy (158 pg/ml), and further increased in late pregnancy
with greatly increased scatter (215 pg/ml), as seen in fig
ure 8. This is statistically significant, and similar to the
patterns found by Lewis et al. (77) and Bolton et al. (81).
6-keto PGFjq was found to be lower in preeclamptics
(149 pg/ml) as compared to normal women during the twenty-
seventh week of gestation or later (191 pg/ml), but this
difference was not statistically significant. If the assay
was valid, this data would significant to help support the
theory that decreased peripheral levels of PGI2 might be an
operant mechanism in preeclampsia-eclampsia.
Another finding was the statisically significant (p 0.05)
correlation of 6-keto PGFjq with platelet count in women
with preeclampsia. This could be expained two ways:
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i) A decrease in prostacyclin in vivo caused an inbal-
ance in the PGI2/TXA2 ratio, leading to increased intravas
cular coagulation and platelet consumption, and therefore
lowered platelet count.
ii) A cross-reacting substance was released from the
platelets upon sample collection.
It is difficult to distinguish between these possibilities
without verification by GC-MS.
The results of this study offers some data that would
be tempting to accept as evidence that peripheral 6-keto
PGFxq , and therefore, PGI2, is increased in normal preg
nancy and decreased in women with preeclampsia. This can
not be accepted with enthusiasm beause assay parameters v/ere
not shown to be valid. GC-MS measurement of a subset of the
samples nay show whether 6-keto PGFjq measured by RIA was
preoportional to the 6-keto PGFiq in the sample. Such evi
dence would make the findings of this study significant in
the study of peripheral PGI2 in preeclampsia.
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VIII. Summary
Prostacyclin production and activity in preeclampsia-
eclampsia is currenly under investigation at several labor
atories. Because of prostacyclin's various effects (plate
let aggregation inhibition, vasodilation, stimulation of
renin release, and possible regulator of the hypertensive
effects of angiotensin II), an increase in the peripheral
activity of this chemical would explain much of the altered
physiology of normal pregnancy. A relative decrease in per
ipheral and local action could theoretically tie together
the many pathophysiological findings of preeclampsia-eclamp
sia.
Therefore, plasma 6-keto PGFiq, the stable nonenzymatic
metabolite of prostacyclin, was measured in women with pre-
eclampsiaand in those of various gestational ages having an
uncomplicated pregnancy. The detection method, radioimmuno
assay, could not be internally validated. It appears that
the major problem with the assay is in sample preparation.
Plasma 6-keto PGFjq may decrease in those women with pre
eclampsia compared to normals of the same gestational age , as
shown in this study. An increase was seen throughout normal
orecnancy. In addition, plasma 6-keto PGFaq was seen
7^
to correlate with platelet count in the preeclamptic wo
men.
These results cannot be accepted as reliable, but in
stead should be considered as impetus for further study.
Gas chromatography-mass spectrometry of some of the samples
from the study could be used for verification. Platelet
aggregation inhibition bioassay with confirmation by GC-MS,
is probably the most reliable detection method available
to date, and would be the best method for further study.
If FGI2 activity and levels are truly decreased in pre
eclampsia, not only does the mechanism of the disease become
much more clear, but a more acceptable treatment modality
for the disease is suggested.
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